Trio Medicines

Trio Medicines is a private, preclinical/clinical-stage biotech company developing a small pipeline of novel small molecules, originating from the work of Nobel Laureate Sir James Black. Its lead asset, netazepide, is a gastrin/CCK2 receptor antagonist with Orphan Drug designation for gastric neuroendocrine tumors (g-NETs) and is seeking a partner for Phase 3 development. The company is wholly funded and supported by its parent, Hammersmith Medicines Research (HMR) Ltd, a major European CRO, which has conducted all of Trio's early trials to date. Trio's strategy involves advancing its pipeline through internal resources while actively seeking development and commercialization partnerships for its key programs.

Expertise in receptor pharmacology (GPCRs) for small molecule drug discovery, with a focus on gastrin/CCK2 receptor antagonists, β-adrenoceptor antagonists, and formyl peptide receptor agonists.

In g-NETs, netazepide competes with other targeted therapies and somatostatin analogs. In acid-related diseases, ceclazepide faces entrenched competition from generic PPIs and H2 blockers. TR4 and TR8 enter crowded fields for β-antagonists and FPR agonists, competing with programs from large pharma and well-funded biotechs.